Souhaitez-vous accéder aux communiqués récents ?

GTB-5550 is now the 3rd TriKE® to enter the clinic and an expansion into a broader solid tumor opportunity, with the Phase 1 trial likely to focus on prostate cancer patients during the dose...

Tacalyx Secures €11 Million to Advance Lead TACA-Targeting ADC Programme Toward the Clinic Berlin, Germany, April 29, 2026 (GLOBE NEWSWIRE) -- Tacalyx, a leader in the discovery and development of...

The goal is to strengthen our intellectual property and to better understand how PRP technology can overcome resistant tumors and age-related diseases.

Conventional chemo hits walls of resistance, brutal toxicity, and minimal progress. PRP changes the game.

The purpose of the study will be used as an important tool to measure the concentration of PRP and its analytes over time upon administration to patients

Kainova Therapeutics announces positive Phase I results for DT‑9081, showing strong safety, target engagement and early anti‑tumor activity.

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...

As we advance toward human trials, we remain committed to delivering hope to patients facing limited options for aggressive cancers from solid tumors.

Filing four provisional patent applications...underscores our relentless drive to protect and expand our groundbreaking proenzyme technology

BetaGlue Receives Belgium Ministry of Health Approval for YntraDose® Clinical Trial in Unresectable Locally Advanced Pancreatic Cancer (uLA-PDAC)